Cardiovascular outcomes trials with DPP-4 inhibitors
This module summarises reported DPP-4 inhibitor CVOTs for saxagliptin (SAVOR-TIMI 53), alogliptin (EXAMINE), sitagliptin (TECOS) and linagliptin (CARMELINA®).
Cardiovascular outcomes trials with DPP-4 inhibitors
DPP-4 inhibitors are an established, non-insulin-based glucose-lowering therapy
CVOTs are being conducted for most compounds within the newer classes of glucose-lowering agents
Mechanism of action of DPP-4 inhibitors
Summary of completed DPP-4 inhibitor CVOTs (1/2)
Summary of completed DPP-4 inhibitor CVOTs (2/2)
Baseline characteristics in completed DPP‑4 inhibitor CVOTs
Baseline CV disease in completed DPP‑4 inhibitor CVOTs
Baseline kidney function in completed DPP-4 inhibitor CVOTs
Baseline medications in completed DPP‑4 inhibitor CVOTs
Summary of DPP-4 inhibitor CVOTs
Kidney endpoints in DPP-4 inhibitor CVOTs
SAVOR-TIMI 53: trial design
EXAMINE: trial design
TECOS: trial design
CARMELINA®: trial design
CAROLINA®: trial design
Primary endpoint in completed DPP-4 inhibitor CVOTs
Hospitalisation for heart failure in completed DPP-4 inhibitor CVOTs
All-cause mortality in completed DPP-4 inhibitor CVOTs
Overview of prespecified kidney endpoints from completed DPP‑4 inhibitor CVOTs
Acute pancreatitis in completed DPP-4 inhibitor CVOTs
Overview of selected AEs from completed DPP-4 inhibitor CVOTs
DPP-4 inhibitor CVOTs: summary
Back-up slides
Overview of CV outcomes from DPP-4 inhibitor CVOTs (1/2)
Overview of CV outcomes from DPP-4 inhibitor CVOTs (2/2)